ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed high-risk endometrial cancer (570).

Autor: Slomovitz, Brian¹ (AUTHOR), Mirza, Mansoor² (AUTHOR), Lortholary, Alain³ (AUTHOR), Vergote, Ignace⁴ (AUTHOR), Cibula, David⁵ (AUTHOR), Walther, Axel⁶ (AUTHOR), Savarese, Antonella⁷ (AUTHOR), Ginesta, Maria Pilar Barretina⁸ (AUTHOR), Ortac, Firat⁹ (AUTHOR), Papadimitriou, Christos¹⁰ (AUTHOR), Bodnar, Lubomir¹¹ (AUTHOR), Lai, Chyong-Huey¹² (AUTHOR), Hasegawa, Kosei¹³ (AUTHOR), Chen, Xiaojun¹⁴ (AUTHOR), Barber, Emma¹⁵ (AUTHOR), Coleman, Robert¹⁶ (AUTHOR), Keefe, Stephen¹⁷ (AUTHOR), Orlowski, Robert¹⁷ (AUTHOR), Gorp, Toon Van¹⁸ (AUTHOR)

Publikováno v: Gynecologic Oncology. 2022 Supplement 1, Vol. 166, pS278-S278. 1p.